1 | sequential | 3,963 |
2 | timed | 958 |
3 | alternating | 674 |
4 | escalating | 363 |
5 | bonferroni | 356 |
6 | orthogonal | 327 |
7 | provocative | 202 |
8 | step-down | 149 |
9 | discontinuous | 136 |
10 | step-up | 120 |
11 | conjoint | 80 |
12 | staircase | 41 |
13 | fixed-time | 39 |
14 | ultra-short | 34 |
15 | subgroup-specific | 32 |
16 | tukey-kramer | 32 |
17 | up-down | 32 |
18 | patient-driven | 27 |
19 | group-sequential | 26 |
20 | yates | 26 |
21 | holm | 21 |
22 | think-aloud | 20 |
23 | roentgen | 18 |
24 | buteyko | 15 |
25 | gnrh-antagonist | 15 |
26 | postradiation | 15 |
27 | 8-foot | 14 |
28 | o'brien-fleming | 14 |
29 | duct-to-mucosa | 13 |
30 | every-3-weeks | 12 |
31 | standardly-tailored | 12 |
32 | steri-strips | 12 |
33 | stepdown | 11 |
34 | intra-renal | 10 |
35 | near-optimal | 10 |
36 | veridical | 10 |
37 | neyman | 9 |
38 | tadalafil/finasteride | 9 |
39 | bonferroni-holm | 8 |
40 | direct-lateral | 8 |
41 | fam2 | 8 |
42 | notional | 8 |
43 | postconsolidation | 8 |
44 | smartphone-assisted | 8 |
45 | concentration-guided | 7 |
46 | dft-d3 | 7 |
47 | dose-reduced | 7 |
48 | holm-sidak | 7 |
49 | mid-p | 7 |
50 | non-reperfusion | 7 |
51 | nop-47 | 7 |
52 | pre-slaughter | 7 |
53 | therapy.the | 7 |
54 | toggle | 7 |
55 | alternant | 6 |
56 | bihormonal | 6 |
57 | experiment-wide | 6 |
58 | fh-based | 6 |
59 | four-weekly | 6 |
60 | non-sequential | 6 |
61 | posterior-only | 6 |
62 | progesterone-based | 6 |
63 | rph2 | 6 |
64 | spouse/marital | 6 |
65 | step-and-shoot | 6 |
66 | teaming | 6 |
67 | titrate-to-goal | 6 |
68 | unaugmented | 6 |
69 | updosing | 6 |
70 | choice-based | 5 |
71 | coulometric | 5 |
72 | fixed-dosage | 5 |
73 | inspirational | 5 |
74 | non-parenteral | 5 |
75 | rbfa | 5 |
76 | savage | 5 |
77 | solution-phase | 5 |
78 | 'persistent | 4 |
79 | 1,990 | 4 |
80 | across-cluster | 4 |
81 | alpins | 4 |
82 | benjamini-hochberg | 4 |
83 | glycerol-induced | 4 |
84 | l1-dfo | 4 |
85 | nonsequential | 4 |
86 | ovsynch-timed | 4 |
87 | post-cap | 4 |
88 | post-transit | 4 |
89 | target-absent | 4 |
90 | 4-liter | 3 |
91 | all-patient | 3 |
92 | bartlett-type | 3 |
93 | bonferonni | 3 |
94 | bonferroni-type | 3 |
95 | capsinoid | 3 |
96 | cc/gn/gnrh-ant | 3 |
97 | citizen-science | 3 |
98 | dhp-sensitive | 3 |
99 | gene-wide | 3 |
100 | hadronic | 3 |
101 | intracerebellar | 3 |
102 | intracor | 3 |
103 | intraintestinal | 3 |
104 | non-synchronized | 3 |
105 | placebo/finasteride | 3 |
106 | rhtsh-stimulated | 3 |
107 | 'cooling | 2 |
108 | 'opening | 2 |
109 | +u | 2 |
110 | 0.24-0.81 | 2 |
111 | beyer | 2 |
112 | bonferroni/dunn | 2 |
113 | citrulline-malate | 2 |
114 | clinically-approved | 2 |
115 | cobalt-based | 2 |
116 | deltamean | 2 |
117 | early-evening | 2 |
118 | ellipson | 2 |
119 | enhanced-care | 2 |
120 | field-in-field | 2 |
121 | intra-mpfc | 2 |
122 | linear-derived | 2 |
123 | multicontrast | 2 |
124 | multiresponse | 2 |
125 | nebulizable | 2 |
126 | nutriological | 2 |
127 | ornidazole-based | 2 |
128 | per-os | 2 |
129 | post-juice | 2 |
130 | presimulation | 2 |
131 | process-dissociation | 2 |
132 | shift-based | 2 |
133 | shrna1 | 2 |
134 | spin-wave | 2 |
135 | symptom-/rescue-free | 2 |
136 | zero-cell | 2 |
137 | 'binomial | 1 |
138 | 'caustic | 1 |
139 | 'corrosive | 1 |
140 | -uc | 1 |
141 | 10-/20-/30-m | 1 |
142 | 113,044 | 1 |
143 | 1650.27 | 1 |
144 | 220-mmhg | 1 |
145 | 3-section | 1 |
146 | 50,151 | 1 |
147 | 99mtcdtpa | 1 |
148 | all-vessel | 1 |
149 | beam-quality-dependent | 1 |
150 | bi-hippocampal | 1 |
151 | bonferroni-dunn | 1 |
152 | bsse | 1 |
153 | cdkn2a/p16 | 1 |
154 | clusterwise | 1 |
155 | cyclization/c-h | 1 |
156 | data-specific | 1 |
157 | deformation-prone | 1 |
158 | devices-a | 1 |
159 | distortion-compensated | 1 |
160 | doxycycline-warfarin | 1 |
161 | egfr/erbb | 1 |
162 | electric-field-oriented | 1 |
163 | etravirine/clarithromycin | 1 |
164 | evening/bedtime | 1 |
165 | extreme-plausible | 1 |
166 | feedthrough | 1 |
167 | folfiri-c. | 1 |
168 | g-study | 1 |
169 | ganciclovir/aciclovir | 1 |
170 | gemfibrozil/statin | 1 |
171 | glial-fibrillary | 1 |
172 | glycerol-glucose | 1 |
173 | h1-receptor-antagonist | 1 |
174 | holm-bonferroni | 1 |
175 | hsp27-sirna | 1 |
176 | hsp90-sirna | 1 |
177 | hyperopia-full | 1 |
178 | iced-slush | 1 |
179 | khz-frequency | 1 |
180 | kidney-depth | 1 |
181 | levofloxacin-500 | 1 |
182 | menc-conjugates | 1 |
183 | orpaclitaxel/carboplatin | 1 |
184 | ovsynch-based | 1 |
185 | parenteral-oral | 1 |
186 | pharmacy-driven | 1 |
187 | plasmid‑mediated | 1 |
188 | post-bonferroni | 1 |
189 | pre-operative/post-operative | 1 |
190 | prednisone-warfarin | 1 |
191 | sheffé | 1 |
192 | snake-capsule | 1 |
193 | soil/dust | 1 |
194 | spinel-structured | 1 |
195 | substrate/inhibitor/inducer | 1 |
196 | subzonal | 1 |
197 | summinging | 1 |
198 | surgica | 1 |
199 | søren | 1 |
200 | tam-mpa | 1 |
201 | taste-immune | 1 |
202 | ticagrelor/midazolam | 1 |
203 | topo2a/her2 | 1 |
204 | trifluoromethanesulfanylation-cyclization | 1 |
205 | warfarin-doxycycline | 1 |
206 | warfarin-prednisone | 1 |
207 | within-saccade | 1 |
208 | working-substance-dependent | 1 |
209 | yf/je | 1 |
210 | yogic-style | 1 |
211 | z4099/radiation | 1 |
212 | zero-point-energy | 1 |
1 | 'binomial | 1 |
2 | 'caustic | 1 |
3 | 'cooling | 2 |
4 | 'corrosive | 1 |
5 | 'opening | 2 |
6 | 'persistent | 4 |
7 | +u | 2 |
8 | -uc | 1 |
9 | 0.24-0.81 | 2 |
10 | 1,990 | 4 |
11 | 10-/20-/30-m | 1 |
12 | 113,044 | 1 |
13 | 1650.27 | 1 |
14 | 220-mmhg | 1 |
15 | 3-section | 1 |
16 | 4-liter | 3 |
17 | 50,151 | 1 |
18 | 8-foot | 14 |
19 | 99mtcdtpa | 1 |
20 | across-cluster | 4 |
21 | all-patient | 3 |
22 | all-vessel | 1 |
23 | alpins | 4 |
24 | alternant | 6 |
25 | alternating | 674 |
26 | bartlett-type | 3 |
27 | beam-quality-dependent | 1 |
28 | benjamini-hochberg | 4 |
29 | beyer | 2 |
30 | bi-hippocampal | 1 |
31 | bihormonal | 6 |
32 | bonferonni | 3 |
33 | bonferroni | 356 |
34 | bonferroni-dunn | 1 |
35 | bonferroni-holm | 8 |
36 | bonferroni-type | 3 |
37 | bonferroni/dunn | 2 |
38 | bsse | 1 |
39 | buteyko | 15 |
40 | capsinoid | 3 |
41 | cc/gn/gnrh-ant | 3 |
42 | cdkn2a/p16 | 1 |
43 | choice-based | 5 |
44 | citizen-science | 3 |
45 | citrulline-malate | 2 |
46 | clinically-approved | 2 |
47 | clusterwise | 1 |
48 | cobalt-based | 2 |
49 | concentration-guided | 7 |
50 | conjoint | 80 |
51 | coulometric | 5 |
52 | cyclization/c-h | 1 |
53 | data-specific | 1 |
54 | deformation-prone | 1 |
55 | deltamean | 2 |
56 | devices-a | 1 |
57 | dft-d3 | 7 |
58 | dhp-sensitive | 3 |
59 | direct-lateral | 8 |
60 | discontinuous | 136 |
61 | distortion-compensated | 1 |
62 | dose-reduced | 7 |
63 | doxycycline-warfarin | 1 |
64 | duct-to-mucosa | 13 |
65 | early-evening | 2 |
66 | egfr/erbb | 1 |
67 | electric-field-oriented | 1 |
68 | ellipson | 2 |
69 | enhanced-care | 2 |
70 | escalating | 363 |
71 | etravirine/clarithromycin | 1 |
72 | evening/bedtime | 1 |
73 | every-3-weeks | 12 |
74 | experiment-wide | 6 |
75 | extreme-plausible | 1 |
76 | fam2 | 8 |
77 | feedthrough | 1 |
78 | fh-based | 6 |
79 | field-in-field | 2 |
80 | fixed-dosage | 5 |
81 | fixed-time | 39 |
82 | folfiri-c. | 1 |
83 | four-weekly | 6 |
84 | g-study | 1 |
85 | ganciclovir/aciclovir | 1 |
86 | gemfibrozil/statin | 1 |
87 | gene-wide | 3 |
88 | glial-fibrillary | 1 |
89 | glycerol-glucose | 1 |
90 | glycerol-induced | 4 |
91 | gnrh-antagonist | 15 |
92 | group-sequential | 26 |
93 | h1-receptor-antagonist | 1 |
94 | hadronic | 3 |
95 | holm | 21 |
96 | holm-bonferroni | 1 |
97 | holm-sidak | 7 |
98 | hsp27-sirna | 1 |
99 | hsp90-sirna | 1 |
100 | hyperopia-full | 1 |
101 | iced-slush | 1 |
102 | inspirational | 5 |
103 | intra-mpfc | 2 |
104 | intra-renal | 10 |
105 | intracerebellar | 3 |
106 | intracor | 3 |
107 | intraintestinal | 3 |
108 | khz-frequency | 1 |
109 | kidney-depth | 1 |
110 | l1-dfo | 4 |
111 | levofloxacin-500 | 1 |
112 | linear-derived | 2 |
113 | menc-conjugates | 1 |
114 | mid-p | 7 |
115 | multicontrast | 2 |
116 | multiresponse | 2 |
117 | near-optimal | 10 |
118 | nebulizable | 2 |
119 | neyman | 9 |
120 | non-parenteral | 5 |
121 | non-reperfusion | 7 |
122 | non-sequential | 6 |
123 | non-synchronized | 3 |
124 | nonsequential | 4 |
125 | nop-47 | 7 |
126 | notional | 8 |
127 | nutriological | 2 |
128 | o'brien-fleming | 14 |
129 | ornidazole-based | 2 |
130 | orpaclitaxel/carboplatin | 1 |
131 | orthogonal | 327 |
132 | ovsynch-based | 1 |
133 | ovsynch-timed | 4 |
134 | parenteral-oral | 1 |
135 | patient-driven | 27 |
136 | per-os | 2 |
137 | pharmacy-driven | 1 |
138 | placebo/finasteride | 3 |
139 | plasmid‑mediated | 1 |
140 | post-bonferroni | 1 |
141 | post-cap | 4 |
142 | post-juice | 2 |
143 | post-transit | 4 |
144 | postconsolidation | 8 |
145 | posterior-only | 6 |
146 | postradiation | 15 |
147 | pre-operative/post-operative | 1 |
148 | pre-slaughter | 7 |
149 | prednisone-warfarin | 1 |
150 | presimulation | 2 |
151 | process-dissociation | 2 |
152 | progesterone-based | 6 |
153 | provocative | 202 |
154 | rbfa | 5 |
155 | rhtsh-stimulated | 3 |
156 | roentgen | 18 |
157 | rph2 | 6 |
158 | savage | 5 |
159 | sequential | 3,963 |
160 | sheffé | 1 |
161 | shift-based | 2 |
162 | shrna1 | 2 |
163 | smartphone-assisted | 8 |
164 | snake-capsule | 1 |
165 | soil/dust | 1 |
166 | solution-phase | 5 |
167 | spin-wave | 2 |
168 | spinel-structured | 1 |
169 | spouse/marital | 6 |
170 | staircase | 41 |
171 | standardly-tailored | 12 |
172 | step-and-shoot | 6 |
173 | step-down | 149 |
174 | step-up | 120 |
175 | stepdown | 11 |
176 | steri-strips | 12 |
177 | subgroup-specific | 32 |
178 | substrate/inhibitor/inducer | 1 |
179 | subzonal | 1 |
180 | summinging | 1 |
181 | surgica | 1 |
182 | symptom-/rescue-free | 2 |
183 | søren | 1 |
184 | tadalafil/finasteride | 9 |
185 | tam-mpa | 1 |
186 | target-absent | 4 |
187 | taste-immune | 1 |
188 | teaming | 6 |
189 | therapy.the | 7 |
190 | think-aloud | 20 |
191 | ticagrelor/midazolam | 1 |
192 | timed | 958 |
193 | titrate-to-goal | 6 |
194 | toggle | 7 |
195 | topo2a/her2 | 1 |
196 | trifluoromethanesulfanylation-cyclization | 1 |
197 | tukey-kramer | 32 |
198 | ultra-short | 34 |
199 | unaugmented | 6 |
200 | up-down | 32 |
201 | updosing | 6 |
202 | veridical | 10 |
203 | warfarin-doxycycline | 1 |
204 | warfarin-prednisone | 1 |
205 | within-saccade | 1 |
206 | working-substance-dependent | 1 |
207 | yates | 26 |
208 | yf/je | 1 |
209 | yogic-style | 1 |
210 | z4099/radiation | 1 |
211 | zero-cell | 2 |
212 | zero-point-energy | 1 |
1 | folfiri-c. | 1 |
2 | levofloxacin-500 | 1 |
3 | 1,990 | 4 |
4 | 50,151 | 1 |
5 | 0.24-0.81 | 2 |
6 | shrna1 | 2 |
7 | rph2 | 6 |
8 | fam2 | 8 |
9 | topo2a/her2 | 1 |
10 | dft-d3 | 7 |
11 | 113,044 | 1 |
12 | cdkn2a/p16 | 1 |
13 | 1650.27 | 1 |
14 | nop-47 | 7 |
15 | devices-a | 1 |
16 | surgica | 1 |
17 | rbfa | 5 |
18 | hsp90-sirna | 1 |
19 | hsp27-sirna | 1 |
20 | tam-mpa | 1 |
21 | 99mtcdtpa | 1 |
22 | duct-to-mucosa | 13 |
23 | egfr/erbb | 1 |
24 | intra-mpfc | 2 |
25 | data-specific | 1 |
26 | subgroup-specific | 32 |
27 | hadronic | 3 |
28 | coulometric | 5 |
29 | 'caustic | 1 |
30 | -uc | 1 |
31 | dose-reduced | 7 |
32 | glycerol-induced | 4 |
33 | concentration-guided | 7 |
34 | timed | 958 |
35 | ovsynch-timed | 4 |
36 | standardly-tailored | 12 |
37 | spinel-structured | 1 |
38 | choice-based | 5 |
39 | ornidazole-based | 2 |
40 | progesterone-based | 6 |
41 | ovsynch-based | 1 |
42 | fh-based | 6 |
43 | shift-based | 2 |
44 | cobalt-based | 2 |
45 | plasmid‑mediated | 1 |
46 | rhtsh-stimulated | 3 |
47 | distortion-compensated | 1 |
48 | electric-field-oriented | 1 |
49 | unaugmented | 6 |
50 | smartphone-assisted | 8 |
51 | linear-derived | 2 |
52 | clinically-approved | 2 |
53 | non-synchronized | 3 |
54 | capsinoid | 3 |
55 | field-in-field | 2 |
56 | think-aloud | 20 |
57 | post-juice | 2 |
58 | citizen-science | 3 |
59 | within-saccade | 1 |
60 | tadalafil/finasteride | 9 |
61 | placebo/finasteride | 3 |
62 | gene-wide | 3 |
63 | experiment-wide | 6 |
64 | symptom-/rescue-free | 2 |
65 | fixed-dosage | 5 |
66 | savage | 5 |
67 | therapy.the | 7 |
68 | yf/je | 1 |
69 | nebulizable | 2 |
70 | extreme-plausible | 1 |
71 | toggle | 7 |
72 | snake-capsule | 1 |
73 | yogic-style | 1 |
74 | fixed-time | 39 |
75 | evening/bedtime | 1 |
76 | warfarin-doxycycline | 1 |
77 | deformation-prone | 1 |
78 | warfarin-prednisone | 1 |
79 | taste-immune | 1 |
80 | bonferroni-type | 3 |
81 | bartlett-type | 3 |
82 | enhanced-care | 2 |
83 | staircase | 41 |
84 | solution-phase | 5 |
85 | clusterwise | 1 |
86 | multiresponse | 2 |
87 | glycerol-glucose | 1 |
88 | bsse | 1 |
89 | citrulline-malate | 2 |
90 | spin-wave | 2 |
91 | 'corrosive | 1 |
92 | provocative | 202 |
93 | pre-operative/post-operative | 1 |
94 | dhp-sensitive | 3 |
95 | 220-mmhg | 1 |
96 | summinging | 1 |
97 | 'cooling | 2 |
98 | teaming | 6 |
99 | o'brien-fleming | 14 |
100 | 'opening | 2 |
101 | early-evening | 2 |
102 | updosing | 6 |
103 | escalating | 363 |
104 | alternating | 674 |
105 | benjamini-hochberg | 4 |
106 | cyclization/c-h | 1 |
107 | feedthrough | 1 |
108 | iced-slush | 1 |
109 | kidney-depth | 1 |
110 | bonferonni | 3 |
111 | bonferroni | 356 |
112 | holm-bonferroni | 1 |
113 | post-bonferroni | 1 |
114 | holm-sidak | 7 |
115 | veridical | 10 |
116 | nutriological | 2 |
117 | 'binomial | 1 |
118 | sequential | 3,963 |
119 | non-sequential | 6 |
120 | group-sequential | 26 |
121 | nonsequential | 4 |
122 | near-optimal | 10 |
123 | intra-renal | 10 |
124 | intraintestinal | 3 |
125 | orthogonal | 327 |
126 | inspirational | 5 |
127 | notional | 8 |
128 | bihormonal | 6 |
129 | subzonal | 1 |
130 | titrate-to-goal | 6 |
131 | bi-hippocampal | 1 |
132 | direct-lateral | 8 |
133 | non-parenteral | 5 |
134 | parenteral-oral | 1 |
135 | spouse/marital | 6 |
136 | all-vessel | 1 |
137 | zero-cell | 2 |
138 | hyperopia-full | 1 |
139 | 10-/20-/30-m | 1 |
140 | ticagrelor/midazolam | 1 |
141 | holm | 21 |
142 | bonferroni-holm | 8 |
143 | deltamean | 2 |
144 | neyman | 9 |
145 | roentgen | 18 |
146 | søren | 1 |
147 | patient-driven | 27 |
148 | pharmacy-driven | 1 |
149 | etravirine/clarithromycin | 1 |
150 | doxycycline-warfarin | 1 |
151 | prednisone-warfarin | 1 |
152 | orpaclitaxel/carboplatin | 1 |
153 | gemfibrozil/statin | 1 |
154 | bonferroni-dunn | 1 |
155 | bonferroni/dunn | 2 |
156 | non-reperfusion | 7 |
157 | postconsolidation | 8 |
158 | process-dissociation | 2 |
159 | z4099/radiation | 1 |
160 | postradiation | 15 |
161 | presimulation | 2 |
162 | trifluoromethanesulfanylation-cyclization | 1 |
163 | 3-section | 1 |
164 | ellipson | 2 |
165 | step-down | 149 |
166 | up-down | 32 |
167 | stepdown | 11 |
168 | l1-dfo | 4 |
169 | buteyko | 15 |
170 | mid-p | 7 |
171 | post-cap | 4 |
172 | step-up | 120 |
173 | intracerebellar | 3 |
174 | substrate/inhibitor/inducer | 1 |
175 | tukey-kramer | 32 |
176 | pre-slaughter | 7 |
177 | 4-liter | 3 |
178 | across-cluster | 4 |
179 | beyer | 2 |
180 | ganciclovir/aciclovir | 1 |
181 | intracor | 3 |
182 | menc-conjugates | 1 |
183 | yates | 26 |
184 | every-3-weeks | 12 |
185 | alpins | 4 |
186 | per-os | 2 |
187 | steri-strips | 12 |
188 | discontinuous | 136 |
189 | post-transit | 4 |
190 | cc/gn/gnrh-ant | 3 |
191 | alternant | 6 |
192 | working-substance-dependent | 1 |
193 | beam-quality-dependent | 1 |
194 | all-patient | 3 |
195 | target-absent | 4 |
196 | 'persistent | 4 |
197 | conjoint | 80 |
198 | 8-foot | 14 |
199 | step-and-shoot | 6 |
200 | ultra-short | 34 |
201 | multicontrast | 2 |
202 | gnrh-antagonist | 15 |
203 | h1-receptor-antagonist | 1 |
204 | soil/dust | 1 |
205 | +u | 2 |
206 | khz-frequency | 1 |
207 | g-study | 1 |
208 | zero-point-energy | 1 |
209 | four-weekly | 6 |
210 | posterior-only | 6 |
211 | glial-fibrillary | 1 |
212 | sheffé | 1 |